Disease	Head and neck cancers
Stage of Disease/Treatment	Metastatic/advanced
Prior Therapy	One prior regimen
Type of Study	Phase I, expansion cohort
Primary Endpoint	Safety
Additional Details of Endpoints or Study Design	Co‐primary objectives of the HNSCC expansion cohort were to (a) characterize the safety, tolerability, and dose‐limiting toxicities (DLTs) of cemiplimab in combination with RT, cyclophosphamide, and GM‐CSF and (b) evaluate the efficacy of cemiplimab in combination with RT, cyclophosphamide, and GM‐CSF by measuring ORR.
Investigator's Analysis	Level of activity did not meet planned endpoint